Zydus partners with Apollo Hospitals to bring Shield cancer detection test to India

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+4.0%1-day move

₹1101.60

prior close

₹1127.80

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.0+0.1+0.1+0.5+4.0+4.6+4.1+5.4+4.4+2.9+0.7———

Up moveDown movePending

AI summary

Zydus Lifesciences has signed an MoU with Apollo Hospitals to offer the Shield Multi-Cancer Detection test in India. The blood-based screening detects 10 common cancers including breast, lung, colorectal, prostate and ovarian in people aged 45 and above. It has FDA Breakthrough Device Designation. Cancer causes about 9 percent of non-communicable disease deaths in India, with 1.41 million new cases and 900,000 deaths reported in 2022. The partnership will boost early cancer screening through Apollo's hospital network.

Likely market impact

Expands Zydus diagnostics portfolio and oncology presence in India via Apollo and Guardant Health partnerships. Positive for long-term growth.